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Abstract
Purpose This study examines the effect of sodium
metabisulphite (SMB) as an antioxidant on the stability and
release of various model drugs, namely, propranolol HCl, the-
ophylline and zonisamide from the polyethylene oxide (PEO)
tablets. The antioxidant was used to minimise degradation and
instability of the manufactured tablets when stored at 40 °C
(55 ± 5% RH) over 8 weeks.
Method Multiple batches of tablets weighing 240mg (50%w/
w) with a ratio of 1:1 drug/polymer and 1% (w/w) sodium
metabisulphite containing different model drugs and various
molecular weights of PEO 750 and 303 were produced.
Results The results indicated that the use of sodium
metabisulphite marginally assisted in reducing drug release
and degradation via oxidation in propranolol HCl tablets con-
taining both PEO 750 and 303. In the case of poorly and semi-
soluble drugs (zonisamide and theophylline), the formulations
with both PEO showed entirely superimposable phenomenon
and different release profiles compared to control samples
(matrices without SMB). DSC study demonstrated the modi-
fications of the polymer due to degradation and observed the
effect of SMB on the thermal degradation of the PEO
matrices.
Conclusion The use of antioxidant has assisted in retaining
the stability of the manufactured tablets with different model
drugs especially those with the highly soluble drug that are
susceptible to rapid degradation. This has been reflected by an
extended release profile of various drugs used at various
stages of the storage time up to 8 weeks.
Keywords Sodiummetabisulphite (SMB) . Antioxidant .
Dissolution rates . PEO .Molecular weight .Matrix tablets
Introduction
Chemical degradation may affect the physical appearance
and dissolution rates, which are important factors relating
to the stability of the manufactured tablets. The chemical
degradation of the active substance from the manufactured
tablets can reduce the amount of drug available to the
patient, making it questionable by the regulatory bodies.
Among various factors, namely, temperature, solvent, pH,
light and oxygen, are some examples that can affect the
drug stability. In addition, excipients can cause stability
problems as well due to their direct chemical reactions
with the drug molecules [1, 2]. Hydrophilic matrix tech-
nology is frequently used to develop controlled release
drug delivery systems [3] as it provides convenient re-
lease profiles for a wide range of therapeutic drugs and
enhances the patient compliances [4]. It has been reported
that a robust formulation strategy makes it easy to
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manufacture at an economical cost with a good in vivo
and in vitro correlation [5, 6]. The hydrophilic polymers
commonly used to develop controlled release formula-
tions initiate a prompt and consistent hydration resulting
in the formation of the gel layer that helps retain structural
integrity and inhibits tablet disintegration [7, 8].
The outer layer allows for the disentanglement of the
polymer from the surface of the matrix when it eventual-
ly reaches a dilution point due to its highly hydrated
nature [4, 9, 10]. The gel layer is then continually re-
placed with the hydrated polymer from inside the core.
Lapidus and Lordi (1966) states, Bthe release of a drug
from the hydrophilic matrix relies on swelling of the ma-
trix, dissolution of the drug, and diffusion and erosion
properties of the gel layer^ [11]. However, the mecha-
nism of drug release is influenced by both the solubility
and dose of the drug, type and quantity of fillers and the
polymer [12, 13]. The solubility of the tablet composition
is important, as it dictates the rate and extent of drug
release from the tablets as well as the polymer hydration
and swelling [4, 14–17].
Recently, polyethylene oxide (PEO) has been used as
one of the most important materials in the pharmaceutical
industry mainly because of its low toxicity, availability in
a range of molecular weight/viscosity grades, wide regu-
latory acceptances and insensitivity to the pH of the bio-
logical medium, high water swellability and erosion char-
acteristics [18–21]. It has been reported that the molecu-
lar weight of the matrix determines the release rate of the
model drug [19, 22, 23]. A study [1, 24], outlined that
the higher molecular weight PEO involves a combination
of swelling and diffusion whereas the lower molecular
weight PEO inhibits a swelling and erosion as the main
mechanism of drug release. Sodium metabisulphite is a
crystalline powder that is readily soluble in water. It is
mainly used as a preservative in some drug and food
preparation because of its anti-oxidant properties. It acts
as an oxygen scavenger to eliminate dissolved oxygen
from water. It is stable under normal conditions and is
hygroscopic in nature [25, 26].
Oxidative degradation is highly likely as PEO can un-
dergo an autoxidation resulting in the degradation of the
formulations. The use of antioxidant can eliminate degra-
dation to a large extent, thus controlling the unexpected
release of the drug as a result of the degradation of the
carrier matrices. This research examined the effect of so-
dium metabisulphite (SMB) as an antioxidant on the sta-
bility of PEO 750 and 303 tablet formulations containing
various soluble model drugs as well as their release rates.
The effect of SMB to control the release rates of various
model drugs as a function to minimise the degradation
and instability of PEO matrix tablets when stored at
40 °C (55 ± 5% RH) for 8 weeks was explored.
Materials and Methods
Materials
Propranolol HCl, theophylline, zonisamide and sodium
metabisulphite (>97%) (MW = 190.10) were provided by
Acros organics (Geel, Belgium). Sentry polyox WSR 750
(MW 300,000), LEO NF and Sentry polyox WSR 303
(MW = 7,000,000), LEO NF, were kindly donated by
Colorcon Ltd. (Dartford, Kent, UK). Magnesium stearate
(MgSt ) was purchased f rom Fischer Sc ien t i f i c
(Loughborough, UK). Deionised water was supplied by
Medway School of Pharmacy (Kent, UK).
True Density Measurement of Powders
In order to evaluate any changes in the true density of powders
before and after storage times (0, 2, 4 and 8 weeks), an ultra-
pycnometer 1000 (Qunatochrom, USA) was used. To carry
out this test, about 3–5 g of sample was used and the results
are the mean and standard deviation of three determinations.
Tablet dimensions were obtained using an electronic digital
calliper (Fisher Scientific, Loughborough, UK).
Tablet Preparation
Multiple batches of tablets weighing 240 mg with a
drug/polymer 1:1 ratio (50:50% w/w) containing different
model drugs and various molecular weights of polyox 750
and 303 were prepared. Batches also contained 1% w/w sodi-
um metabisulphite as an antioxidant. All formulations were
mixed in a Turbula system manufactured by Schatz Willy A
(Basel, Switzerland) for a period of 10 min. Tablet matrices
with a target weight of 240 mg were prepared using a manual
tablet press produced by Enerpac (Northumberland, UK),
equipped with an 8-mm flat-faced die and punch set, at a
compression pressure of 1500 psi. The dye and punch were
lubricated with a 1% w/v mixture of magnesium stearate and
acetone. The tablets were stored in a covered close glass con-
tainer in an oven at 40 °C (55 ± 5% RH). At different time
intervals (0, 2, 4 and 8 weeks), the release rate of the tablets
was determined from dissolution tests.
Physical Characterisation of Tablets
The crushing strength (hardness) test (n = 3) was carried
out using a hardness tester DR SCHLEUNIGER obtained
from JB Pharmatron Ltd. (Northamptonshire, UK). The
averages of these three tablets were calculated as mean
results.
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Dissolution Study
In vitro drug release from matrix tablets was carried out using
the USP paddle method [27]. The dissolution tester
manufactured by Erweka (Heusenstamm, Germany) was used
to monitor the dissolution profiles of the model drugs in the
matrix tablets. The dissolution medium consisted of 900 ml of
distilled water at 37 ± 0.1 °C, and the paddles were rotated at
100 rpm. The sink condition was maintained for all the three
drugs used in the present study according to their solubility in
the water (0.8, 13 and 50 mg/ml for zonisamide, theophylline
and propranolol HCl, respectively), and the dose used in the
present study was 120 mg for each drug. From the dissolution
flask, samples were withdrawn at preselected time intervals at
15-min intervals up to 2 h and after that, every 30 min up to
12 h using a peristaltic pump. The concentrations of drugs in
the samples were determined by UV spectrophotometer at
271, 270 and 290 nm for theophylline, zonisamide and pro-
pranolol HCl, respectively, using UV-visible recording spec-
trophotometer (Shimadzu, Kyoto, Japan).
Kinetics Models
In order to study the mechanism of drug release from matrix
tablets, the release data were fitted to well-known empirical
equation proposed by Korsmeyer and Peppas [28].
Mt=M∞ ¼ Kptn ð1Þ
logMt=M∞ ¼ logKp þ nlogt ð2Þ
whereMt/M is the fractional drug release, t is the release time,
Kp denotes as the kinetic constant and n is the diffusion expo-
nent characteristics of the release mechanism. For a cylinder
matrix that can swell, 0.89 < n < 1 indicates a super case II,
and n = 0.89 shows for the case II release kinetics, while
0.45 < n < 0.89 shows anomalous release kinetics and when
n < 0.45 shows Fickian diffusion release kinetics [28, 29].
Similarity Factor (f2) Measurement
To determine the similarity between the obtained drug release
profiles, the f2 factor proposed byMoore and Flanner [30] was
calculated according to Eq. (1):
f 2 ¼ 50log 1þ 1=∑nn−1wt Rt−Ttð Þ2
h i−0:5
 100
 
ð3Þ
This being a mathematical treatment of the dissolution da-
ta, where n is the number of test points for the samples, wt is
the optional weight factor, Rt is the reference assay at time
point t and Tt is the test assay at time point t. An f2 value
between 50 and 100 suggests a similarity between the two
release profiles, and the closer the value is to 100, the more
similar or identical the profiles are. Also, dissimilarity occurs
with decreasing values less than 50 [30].
Dissolution Parameters
Dissolution efficiency (DE720min) and mean dissolution time
(MDT) were used to represent the dissolution rate from vari-
ous preparations. The DE of a pharmaceutical dosage forms is
defined as the area under the dissolution curve up to a certain
time, t, expressed as percentage of the area of the rectangle
described by 100% dissolution in the same time. DE is de-
scribed by Eq. (4) [31]:
DE ¼
∫
t
0
y dt
y100  t
 100% ð4Þ
where y is the percent drug release as the function of time, t is
the total time of drug release and y100 is 100% drug release. An
alternative parameter that describes the dissolution rate is the
mean dissolution time (MDT), the most likely time for a mol-
ecule to be dissolved from a solid dosage form. Therefore,
MDT is the mean time for the drug to dissolve under in vitro
dissolution conditions. This is calculated using Eq. (5) [31]:
MDT ¼
∑
n
j−1
t jΔM j
∑
n
j−1
ΔM j
ð5Þ
where j is the sample number, tj is the midpoint of the jth time
period (easily calculated with [t + (t − 1)]/2) and ΔMj is the
additional amount of drug dissolved between tj and t − 1.
SPSS software was then used to calculate the cumulative per-
centages of DE and MDT.
Differential Scanning Calorimetry (DSC)
DSC was used to characterise the thermal properties of the
polymers. Metter Toledo DSC (Beaumont Leys, Leicester,
UK) system TS0801RO sample robot was used to measure
thermal properties (enthalpy) and melting point of the poly-
mer, in the physical mixture. Approximately 4–5 mg of sam-
ple was weighed and heated ranging from 25 to 280 °C at a
scanning rate of 10 °C/min in sealed no thematic aluminium
pans for 28 min under nitrogen gas.
Statistical Analysis
The samples were compared with the reference (control) by an
analysis of variance (ANOVA), following Dunnet’s test. The
SPSS software was used to perform all statistical analyses.
The P value <0.05 was considered as significant. All the re-
sults are expressed as mean ± standard deviation.
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Results and Discussion
The Influence of Storage Conditions on True Density
In order to investigate any changes in true density over storage
condition, the true density measurement of matrices contain-
ing sodium metabisulphite was carried out for all formula-
tions. The results indicated that there was no significant dif-
ference (p > 0.05) on the true densities of PEO polymer for-
mulations in presence of sodium metabisulphite stored over
8 weeks at 40 °C. The results showed that the range of true
density for fresh samples was between 1.29 and 1.33 g/cm3.
As been claimed that there was no significant change observed
in the true density of polymer formulations stored over
8 weeks, the values of the true density remained approximate-
ly the same (1.27–1.30 g/cm3) as the fresh samples.
The Influence of Sodium Metabisulphite on Hardness
of Various Drug Tablet Matrices
Table 1 shows the effect of sodiummetabisulphite at a 1% (w/
w) concentration on the hardness of propranolol HCl, theoph-
ylline and zonisamide tablet matrices before and after storage
time. In general, the hardness of the tablets increases as the
molecular weight of the polymer increases. Interestingly, as
shown in Table 1, there was no significant difference between
the hardness of neither the fresh and aged (up to 4 weeks of
storage) propranolol HCl matrices containing the antioxidant
nor tablets prepared with different molecular weight PEO. It
has only been seen that the hardness of the propranolol tablets
was reduced slightly after 8 weeks of storage. This was due to
the presence of the antioxidant that was preventing the possi-
ble degradation of the PEO matrices resulting in almost sim-
ilar hardness. For comparison, the manufactured tablets with-
out the SMB exhibited slightly lower values in the hardness of
the tablets with PEO 750 (time 0 = ~90.2 N and week
4 = ~88.3 N). In contrast, overall results indicate an increase
in tablet hardness over time for semi- and poorly soluble drugs
(theophylline and zonisamide). The molecular weights of the
polymer matrices seemed to play a pivotal role to the increase
in the hardness of the produced tablets. This could be attrib-
uted to the fact that the presence of SMB might reduce the
bonding strength between particles in the matrices at week 0,
which then continues to increase as the storage time increases
over 8 weeks.
The Evaluation Effect of Sodium Metabisulphite at Ratio
(1% w/w) on Release Rate Behaviour of Propranolol HCl
Tablet Matrices
In order to evaluate the effect of sodium metabisulphite on
drug release, propranolol was chosen as a model drug due to
its high solubility in water (solubility of propranolol HCl is
50.0 mg/ml) and results are shown in Fig. 1. The dissolution
profile indicates that there were no significant differences be-
tween the release rates of the tablets at different storage time
for both molecular weight PEO (compare Fig. 1a with b and
c). The results showed that the storage temperature sustained
the drug release process from the matrices from 0 week to
8 weeks compared to that of the ‘control’ formulations (with-
out SMB). As can be seen from Fig. 1 b, c drug release was
controlled for different storage time (2, 4, 8 weeks) when
sodium metabisulphite was incorporated in propranolol HCl
polymer formulations. This can be attributed to an increasing
in viscosity of gel layer and, the formation of a gel layer with a
longer diffusional path with a rise in the concentration of PEO.
This means degradation as results of storage did not happen in
matrices in presence of this antioxidant. This could be depend-
ing on the effect of sodium metabisulphite which dilated pen-
etration of oxygen into the tablet matrices resulting to no deg-
radation, and a loss in molecular weight of PEO did not occur
in PEO. These results complement the previous study carried
out by Shojaee et al. [32] who investigated the effect of dif-
ferent concentrations SMB on release rate of diltiazem HCl
tablet matrices. The results showed that the drug release was
controlled and much slower in the presence of this antioxidant
Table 1 Effect of sodium
metabisulphite on propranolol/
theophylline/zonisamide-polyox
tablet hardness stored at 40 °C
PEO (grade) Time (weeks) Hardness (N)
1% SMB propanolol
Hardness (N)
1% SMB theophylline
Hardness (N)
1% SMB zonisamide
750 0 92.0 ± 0.3 74.3 ± 0.6 78.0 ± 0.1
750 2 92.1 ± 0.2 77.5 ± 0.1 80.0 ± 1.0
750 4 92.0 ± 0.1 81.0 ± 0.7 83.5 ± 0.5
750 8 91.5 ± 0.5 85.5 ± 0.3 85.0 ± 0.2
303 0 98.5 ± 0.5 89.5 ± 0.2 94.0 ± 0.1
303 2 98.2 ± 0.3 91.0 ± 0.5 96.1 ± 0.5
303 4 98.0 ± 0.6 92.0 ± 0.4 99.0 ± 0.2
303 8 97.4 ± 0.4 93.5 ± 0.6 101.5 ± 0.1
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compared to the samples without SMB (compare Fig. 1a with
b and c).
On the basis of above information, some of the features in
the dissolution rates of PEO can be elaborated particularly by
similarity factor (f2) values. All f2 values for PEO 750 (low
molecular weight) and PEO 303 (high molecular weight) are
reported to be greater than 50 when the fresh tablets were
compared to aged polyox matrices which is an indication of
good similarity between their release profiles (Table 2).
Table 3 shows the results of fitting the dissolution data with
the dissolution criteria carried out by calculation DE andMDT
as described by Khan [31]. As can be seen from Table 3,
dissolution efficiency values are reliable with dissolution pro-
files and these data showed that there was no significant dif-
ference between DE data from both PEO 750 and 303. The
results obtained for MDTconfirmed the same trend (with DE)
for both low- and high-molecular-weight PEO, and no major
difference was obtained for MDT during the storage of the
samples (Table 3).This again verified a stable release rate for
both molecular weights PEO in the presence of the antioxi-
dant. For illustration, the dissolution efficiency value of PEO
750 at time 0 was 84.0% whereas this value decreased to
82.0% for tablet matrices stored for 8 weeks at 40 °C.
Slightly different pattern was obtained for PEO 303 with DE
of 57% at 0 and the same value at week 8 (Table 3).
The Evaluation Effect of Sodium Metabisulphite at Ratio
(1% w/w) on Release Rate Behaviour of Zonisamide
and Theophylline Tablet Matrices
In order to cover a wide range of drug solubility, zonisamide, a
very poorly water soluble drug (0.8 mg/ml) and theophylline,
a semi-soluble drug (8 mg/ml) were chosen. The dissolution
results of zonisamide and theophylline from the PEO matrix
tablets in presence of 1% (w/w) SMB are depicted in Figs. 2
and 3. SMB readily reacts with dissolved oxygen and is con-
verted into sodium hydrogen sulphate [33]. The formulations
containing SMB with both PEO 750 and 303 showed entirely
different release profiles compared to the matrices without any
antioxidant. For fresh tablets, within the first 2 h, about 90 and
75% of the drug released from PEO 750 and PEO 303 matri-
ces, respectively, higher than matrices without SMB (compare
Figs. 2a with b and c). At 8 weeks, drug release was further
stalled, with approximately 90% being released after 12 h in a
formulation including PEO 303; however, with time, instead
of increasing, the dissolution decreased slightly. A decelera-
tion of drug release at longer storage time is evident in Fig. 2b,
c for preparations containing sodium metabisulphite; howev-
er, no major fluctuations can be seen with the antioxidant,
proposing that sodium metabisulphite addition has stabilised
the oxidation of the polymer. However, as the release profile
was getting slower with time, there may be problems with a
reproducible in vivo profile.
The difference in the effect of antioxidant is visible in
Figs. 2 and 3 compared to that of Fig. 1, with whereby SMB
dramatically increases dissolution at week 0 to almost 90 and
Fig. 1 Release profile of propranolol batches made with various PEO at
1:1 drug/polymer ratio, containing 1% w/w sodium metabisulphite and
stored at 40 °C. a PEO 750/303 without sodium metabisulphite. b PEO
750 with sodium metabisulphite. c PEO 303 with sodium metabisulphite
Table 2 f2 values of propranolol/theophylline/zonisamide-polyox
tablet matrices containing 1% w/w concentration sodium metabisulphite
at different storage times (2, 4 and 8 weeks)
PEO
(grade)
Storage time
(weeks)
1% SMB
propanolol
1% SMB
theophylline
1% SMB
zonisamide
750 2 67.0 60.0 46.8
750 4 56.7 39.0 37.3
750 8 69.3 36.0 35.4
303 2 60.9 68.1 69.5
303 4 57.6 70.3 37.0
303 8 70.0 64.4 34.2
Time zero was used as a control
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75%within 2 h for PEO 750 and 303, respectively. In contrast,
a sustained release was achieved by SMB incorporation in
propranolol HCl polymer formulations. The probable reason
for this increased drug release could be the ionic property and
solubility of SMB. The presence of sodium ions in the dosage
form itself was reported to cause a rapid disintegration of
extended release HPMC matrix tablets [34]. Sodium
metabisulphite is readily soluble in water, and in the presence
of water, the compound dissociates and forms sodium ion
(Na+) and hydrogen sulphite (HSO3
−) [33]. Higher affinity
between sodium ion and water molecules may have facilitated
the swelling of matrix quickly. It is suggested that the possible
Table 3 Effect of sodium metabisulphite on dissolution parameters of propranolol/theophylline/zonisamide PEO tablet matrices
PEO (grade) Time (week) DE (%)
Propranolol
MDT(h)
Propranolol
DE (%)
Theophylline
MDT (h)
Theophylline
DE (%)
Zonisamide
MDT (h)
Zonisamide
750 0 84.0 1.17 88.0 1.06 89.0 1.11
750 2 79.0 1.27 86.0 1.17 85.0 1.07
750 4 81.0 1.09 84.0 1.25 84.5 1.15
750 8 82.0 1.33 83.0 1.36 84.1 1.25
303 0 57.0 0.82 81.0 1.20 85.0 1.46
303 2 61.0 0.93 79.0 1.19 84.0 1.35
303 4 61.5 0.85 79.0 1.21 78.0 1.44
303 8 57.0 0.91 78.5 1.13 73.0 1.43
DE dissolution efficiency, MDT mean dissolution time
Fig. 2 Release profile of zonisamide batches made with various PEO at
1:1 drug/polymer ratio, containing 1% w/w sodium metabisulphite and
stored at 40 °C. a PEO 750/303 without sodium metabisulphite. b PEO
750 with sodium metabisulphite. c PEO 303 with sodium metabisulphite
Fig. 3 Release profile of theophylline batches made with various PEO at
1:1 drug/polymer ratio, containing 1% w/w sodium metabisulphite and
stored at 40 °C. a PEO 750/303 without sodium metabisulphite. b PEO
750 with sodium metabisulphite. c PEO 303 with sodium metabisulphite
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enhanced drug release exhibited with sodium metabisulphite
is as a result of its high ionic strength, implicating the cloud
point (gelation temperature) of gel layers and affecting their
formation. The higher the ionic strength, the greater the num-
ber of counter-ions available for ion exchange, increasing
drug release through enhanced drug unloading [35].
Regardless of the small quantity of sodium metabisulphite
present within the batches, the interacting ions may be enough
to affect gel layer function, inducing an insufficient barrier and
drug release to considerably differ from SMB and the control
batch (Fig. 2b, c). It is interesting to note that a good similar
pattern release rate was obtained in a formulation containing
semi-soluble drug theophylline with both PEO 750 and 303,
and the results are shown in Fig. 3b, c. The reason for this drug
release was driven for zonisamide tablet matrices earlier in this
study. Although, decreasing in release rate with progressive
storage timewas not noteworthy in theophylline matrices with
PEO 303 (Fig. 3c).
To confirm the dissolution profiles, f2 test was employed to
observe the effect of the antioxidants and results presented in
Table 2 shows that all f2 values (except for PEO 303 at week 2,
f2 = 69.5) are less than 50, which is determined that there were
no similarity between fresh and aged samples, indicating
slower drug release at longer storage time in samples contain-
ing sodium metabisulphite (Table 2). As can be seen from
Table 2, f2 values for PEO 750 and theophylline were in the
same line, although all f2 values were obtained for theophyl-
line and PEO 303 are bigger than 50, which demonstrated
similar release rate for fresh and aged samples.
DE and MDT as described by Khan [31] for zonisamide
and theophylline matrices were carried out to match up to the
dissolution data and results are given in Table 3. Dissolution
efficiency values confirmed that the drug release rate from
various PEO was slower when storage time increased, and a
smaller DE was obtained at longer storage time. For instance,
the dissolution efficiency value of PEO 750 with theophylline
and zonisamide and at time 0 was 88.0 and 89.0% while this
value declined to 83 and 84.1%, respectively, for aged matri-
ces stored for 8 weeks at 40 °C. Similar patterns were ob-
served for the other molecular weight PEO 303 (Table 3).
The results obtained for MDT showed a similar trend for the-
ophylline and zonisamide with fresh PEO 750 tablets being
1.06 and 1.11 h while this value increased to 1.36 and 1.25 h,
respectively, at 8-week storage time which is an indication of
slower drug release for the tablets stored at 40 °C for 8 weeks
(Table 3).
Kinetics Study
In order to evaluate the effect of sodiummetabisulphite on the
mechanism of drug release from the formulations at different
storage times, all release data were plotted in Korsmeyer and
Peppas equation (power lawmodel) which is the best equation
to study the in vitro drug release in such polymeric matrices
[28, 29]. Although the sample preparations may follow zero-
order kinetic, first-order or Higuchi’s model, the results of
kinetic release obtained from the matrices with and without
SMB are given in Tables 4 and 5. The results showed that the
n value for both PEO750 and 303 are between 0.68 and 1.49
which is indicated of anomalous release kinetics and indicates
a super case II for all different formulations shown in Tables 4
and 5.
DSC Analysis
The thermal transitions of the formulations containing SMB
before and after storage were investigated by DSC, and results
are shown in Figs. 4 and 5 and Tables 6 and 7. For propran-
olol, the DSC traces of polyox matrices (PEO 750 and 303)
with and without SMB clearly showed that there is a signifi-
cant shift towards higher temperature when metabisulphite
was present in the PEO 750 and 303 samples. This means that
using the antioxidant could prevent degradation of PEO dur-
ing a longer storage time with increased temperature. These
results obtained via the DSC are summarised in Table 6 in-
cluding the enthalpy, onset and melting peak. It appears from
the table that for samples containing both PEO 750 and 303,
the enthalpy values and temperature of melting peak did not
decrease as the storage time progressed, maintaining almost
similar enthalpies and melting peaks (Table 6).
The DSC traces for zonisamide matrices are presented in
Fig. 5 and Table 7. DSC thermograms (Fig. 5) showed that
presence of the SMB in PEO 750 and 303 polymer matrices
resulted in moving towards higher temperature at longer
Table 4 Effect of storage time onmechanism of drug release of various
soluble drugs in absence and presence of 1%w/w from PEO 750 matrices
Formulation r2 Number
Propranolol HCl
PEO 750 (fresh) 0.97 0.81
PEO 750 (8 weeks) 0.96 1.29
PEO 750 with sodium metabisulphite (1% fresh) 0.93 1.29
PEO 750 with sodium metabisulphite (1%, 8 weeks) 0.95 1.24
Theophylline
PEO 750 (fresh) 0.99 1.11
PEO 750 (8 weeks) 0.98 0.87
PEO 750 with sodium metabisulphite (1% fresh) 0.98 0.87
PEO 750 with sodium metabisulphite (1%, 8 weeks) 0.99 1.21
Zonisamide
PEO 750 (fresh) 0.92 1.15
PEO 750 (8 weeks) 0.97 1.86
PEO 750 with sodium metabisulphite (1% fresh) 0.98 1.44
PEO 750 with sodium metabisulphite (1%, 8 weeks) 0.99 1.49
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storage time and an increase in enthalpies as the storage dura-
tion increased. This means the fast release rate resultant of
using sodium metabisulphite in both PEO 750/303 at week 0
was controlled at longer storage conditions. It is also evident
from Table 7 that there was an increase in the melting peak of
matrices containing sodium metabisulphite, and then, it was
controlled as storage time increased. A quite similar trend for
thermal behaviour for theophylline matrices was observed
(data not shown).
General Discussion
To cover a good range of drug solubility in presence of SMB,
three model soluble drugs, namely, zonisamide, propranolol
HCl and theophylline, with water solubility of 0.8, 60 and
8 mg/ml, respectively, were chosen. The results showed that
the solubility of the drug by itself directly impacted on the
release rate of different types of drugs.Moreover, results clear-
ly demonstrated that sodium metabisulphite is a good candi-
date to prevent degradation in different molecular weight PEO
in highly soluble drugs such as propranolol HCl (60 mg/ml).
The observed results may be deemed expected, according to
previous reports by Shojaee et al. [32], and our data for both
PEO 750 and 303 containing propranolol HCl showed faster
release for aged tablets without sodiummetabisulphite; on the
other hand, drug release was controlled in the presence of this
antioxidant. It is interesting to note that there is no any other
previous research that studied the effect of SMB in sustained
release matrices. The results of the current study also illustrat-
ed that using SMB in the semi- and poorly water-soluble
drugs, such as theophylline and zonisamide, had completely
different effect in the beginning of drug release in terms of
stability in comparison with the fresh samples without this
Fig. 4 DSC thermograms of propranolol-PEO 750 and 303 at 8-week
storage time without and containing 1% w/w sodium metabisulphite
Table 5 Effect of storage time onmechanism of drug release of various
soluble drugs in absence and presence of 1% w/w sodium metabisulphite
from PEO 303 matrices
Formulation r2 Number
Propranolol HCl/ PEO 303 (fresh) 0.99 1.05
PEO 303 (8 weeks) 0.99 0.68
PEO 303 with sodium metabisulphite (1% fresh) 0.81 0.99
PEO 303 with sodium metabisulphite (1%, 8 weeks) 0.98 0.97
Theophylline / PEO 303 (fresh) 0.99 1.04
PEO 303 (8 weeks) 0.99 1.08
PEO 303 with sodium metabisulphite (1% fresh) 0.99 1.04
PEO 303 with sodium metabisulphite (1%, 8 weeks) 0.98 1.06
Zonisamide/ PEO 303 (fresh) 0.99 0.82
PEO 303 (8 weeks) 0.97 0.87
PEO 303 with sodium metabisulphite (1% fresh) 0.99 1.44
PEO 303 with sodium metabisulphite (1%, 8 weeks) 0.97 1.27
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antioxidant, although drug release decreased as storage time
increased. These results particularly are not correlated with the
previous data published by Shojaee et al. [32, 36], who studied
the role of sodium metabisulphite on the release rate of
diltiazem hydrochloride from polyethylene oxide. This was
also a disagreement with earlier data observed in the begin-
ning of this study with propranolol HCl and the reason is
given earlier.
Table 6 Effect of sodium
metabisulphite at 1% w/w on
thermal behaviour of propranolol-
PEO samples750 and 303
samples
PEO samples Enthalpy (J/g) Onset (°C) Melting peak (°C)
750 fresh −135.0 ± 1.0 64.0 ± 1.0 71.0 ± 0.5
750 (week 8) −115.0 ± 0.2 60.0 ± 0.5 67.5 ± 0.1
750 with 1% SMB (week 8) −130.2 ± 0.1 62.0 ± 0.1 70.0 ± 1.0
303 fresh −165.4 ± 1.0 64.0 ± 0.4 71.5 ± 0.1
303 (week 8) −131.5 ± 0.4 62.0 ± 1.0 68.0 ± 0.3
303 with 1% SMB (week 8) −161.0 ± 0.6 63.0 ± 0.2 71.0 ± 0.5
Fig. 5 DSC thermograms for
zonisamide ground matrix tablets,
PEO 750 and 303 with
concentration (1%) sodium
metabisulphite, fresh and stored
for 8 weeks at 40 °C
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Conclusions
The results indicated that the use of sodium metabisulphite
marginally assisted in reducing drug release as a result of the
minimised degradation via oxidation in propranolol HCl tab-
lets containing PEO matrices. In the case of poorly and semi-
soluble drugs (zonisamide and theophylline), the formulations
exhibited superimposable phenomenon with different release
profiles compared to that of those samples without SMB. The
effect of the antioxidant in the tablet formulations is quite
evident in the thermal analysis where the presence of SMB
seemed to have reduced the thermal degradation of the PEO
matrices. Moreover, it was also found that the effect of sodium
metabisulphite on the stability and the release of the drugs
from the matrix tablets were dependants on both the molecular
weight of PEO and the solubility of the drugs used. In conclu-
sion, it can be claimed that overall, the use of an antioxidant in
the formulations has made the manufactured tablets stable
over 8 weeks of storage.
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